Artal Participations S.a r.l. - 17 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
Director, 10%+ Owner
Signature
See Exhibit 99.1
Issuer symbol
LXRX
Transactions as of
17 Feb 2026
Net transactions value
+$2,683,823
Form type
4
Filing time
19 Feb 2026, 16:50:12 UTC
Previous filing
16 Dec 2024
SEC
View on sec.gov

Reporting Owners (7)

Name Relationship Address Signature Signature date CIK
Artal Participations S.a r.l. Director, 10%+ Owner VALLEY PARK 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 19 Feb 2026 0002048403
Artal International S.C.A. Director, 10%+ Owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 19 Feb 2026 0001218180
Artal International Management S.A. Director, 10%+ Owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 19 Feb 2026 0001522131
Artal Group S.A. Director, 10%+ Owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 19 Feb 2026 0001053906
Westend S.A. Director, 10%+ Owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 19 Feb 2026 0001283968
Stichting Administratiekantoor Westend Director, 10%+ Owner H.J.E. WENCKEBACHWEG 252, AMSTERDAM, NETHERLANDS See Exhibit 99.1 19 Feb 2026 0001460840
Wittouck Amaury Director, 10%+ Owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG See Exhibit 99.1 19 Feb 2026 0001841311

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Series B Convertible Preferred Stock Award $2,683,823 +41,290 +11% $65.00 408,435 17 Feb 2026 See Footnotes F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to that certain preferred stock purchase agreement (the "Purchase Agreement") with the Issuer, dated as of January 29, 2026, in connection with the underwriter's partial exercise of their option to purchase additional shares of Issuer common stock par value $0.001 per share (the "Common Stock") in an underwritten public offering, Artal Participations S.a r.l. purchased an additional 41,289.58 shares of Issuer Series B Convertible Preferred Stock, par value $0.01 per share (the "Preferred Stock") at a price of $65.00 per share. Each share of Preferred Stock will automatically convert into 50 shares of Common Stock upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible.
F2 These securities are directly held by Artal Participations S.a r.l.
F3 The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.
F4 Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Remarks:

Invus Public Equities, L.P. directly holds 7,362,368 shares of Common Stock, Invus, L.P. directly owns 35,402,689 shares of Common Stock, Invus US Partners LLC directly owns 5,451,204 shares of Common Stock, Mr. Debbane directly owns 1,654,186 shares of Common Stock, Avicenna Life Sci Master Fund LP directly owns 1,538,462 shares of Common Stock and Artal Participations S.a r.l. directly owns 154,734,327 shares of Common Stock, which securities are reported on separate Form 4 filings. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.